Syneron Medical (ELOS) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Syneron Medical Reports Third Quarter 2015 Revenue of $62.1 Million
November 11, 2015 7:00 AM ESTIRVINE, Calif., Nov. 11, 2015 /PRNewswire/ --Â Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, today announced financial results for the three month period ended September 30, 2015.
Third Quarter 2015 and Recent Non-GAAP[1] Highlights:
Revenue of $62.1 million, compared to $60.3 million in the third quarter 2014, up 3% year-over-year, or 8% in constant currency North American product sales grew 15% year-over-year Non-GAAP gross margin of 57.0%, or 58.9% in constant currency, compared to 55.6% in Q3 2014 Non-GAAP net income of... MoreSyneron Medical Appoints Jeff Nardoci as President of North America Body Shaping Group
November 11, 2015 6:59 AM ESTIRVINE, Calif., Nov. 11, 2015 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today that it has enhanced its North American leadership team with the appointment of Jeff Nardoci as President of its North America Body Shaping Group. In this position, Mr. Nardoci will be responsible for the development and execution of the Company's growth strategies for UltraShape and VelaShape. He will report to Bill Griffing, CEO of Syneron Candela North America.
Amit Meridor, Chief... More
